Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD.

scientific article

Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1176/APPI.AJP.2011.10111705
P932PMC publication ID4132884
P698PubMed publication ID21890793
P5875ResearchGate publication ID51618044

P50authorTimothy WigalQ109420531
Howard B. AbikoffQ109440877
Kwan HurQ114514319
Peter S. JensenQ37383431
Robert D. GibbonsQ46996511
L Eugene ArnoldQ88413008
Benedetto VitielloQ92372542
Brooke S G MolinaQ97529705
Lily HechtmanQ109378466
James M. SwansonQ109401078
Joanne B SevereQ109419684
Laurence L GreenhillQ109420186
P2093author name stringJonathan R Kaltman
Karen Wells
Glen R Elliott
Carol Odbert
P2860cites workThe MTA at 8 Years: Prospective Follow-up of Children Treated for Combined-Type ADHD in a Multisite StudyQ22242740
The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and AdolescentsQ22305963
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>Q28204197
ADHD drugs and cardiovascular riskQ28302969
2000 CDC Growth Charts for the United States: methods and developmentQ29614506
Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trialQ32041811
Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA.Q32041828
Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and womenQ34108099
Sympathetic nervous system activity and ventricular tachyarrhythmias: recent advances.Q35171874
Trends in blood pressure among children and adolescentsQ39281775
Methylphenidate vs dextroamphetamine vs caffeine in minimal brain dysfunction: controlled comparison by placebo washout design with Bayes' analysisQ40975193
Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorderQ43456283
Heart rate and cardiovascular mortality: the Framingham StudyQ43463488
Short-term cardiovascular effects of methylphenidate and adderallQ43605125
Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000.Q43816619
24-hour ambulatory blood pressure monitoring in male children receiving stimulant therapyQ44042907
Cardiovascular effects of methylphenidate in humans are associated with increases of dopamine in brain and of epinephrine in plasmaQ44317525
Cardiac sympathetic nerve activity in patients with hypertrophic cardiomyopathy with malignant ventricular tachyarrhythmiasQ44470510
Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up studyQ44717857
National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorderQ44827148
Sudden death and use of stimulant medications in youths.Q45968311
Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder.Q46037145
Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in childrenQ46719438
Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial.Q46778584
A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorderQ46864359
Cardiovascular effects of mixed amphetamine salts extended release in the treatment of school-aged children with attention-deficit/hyperactivity disorderQ51935749
National Institute of Mental Health Collaborative Multimodal Treatment Study of Children with ADHD (the MTA). Design challenges and choicesQ52256565
Effects of Stimulant Medication on Growth Rates Across 3 Years in the MTA Follow-upQ58822742
Cardiovascular responses of hyperactive children to methylphenidateQ67497473
Pulse rate, coronary heart disease, and death: the NHANES I Epidemiologic Follow-up StudyQ68178040
A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHDQ73256558
Relationship of blood pressure to 25-year mortality due to coronary heart disease, cardiovascular diseases, and all causes in young adult men: the Chicago Heart Association Detection Project in IndustryQ74100393
Overweight, ethnicity, and the prevalence of hypertension in school-aged childrenQ76393401
Sudden death in children and adolescentsQ81051182
Relation of heart rate at rest and long-term (>20 years) death rate in initially healthy middle-aged menQ83142857
Stimulant treatment of ADHD and risk of sudden death in childrenQ84071177
Relative cardiovascular safety of psychostimulants used to treat attention-deficit hyperactivity disorderQ84289023
P433issue2
P407language of work or nameEnglishQ1860
P304page(s)167-177
P577publication date2012-02-01
P1433published inAmerican Journal of PsychiatryQ1935368
P1476titleBlood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD.
P478volume169

Reverse relations

cites work (P2860)
Q28078913A discursive analysis concerning information on "ADHD" presented to parents by the National Institute of Mental Health (USA)
Q83409862ADHD Pharmacotherapy: Rates of Stimulant Use and Cardiovascular Risk
Q38808573ADHD in school-aged youth: Management and special treatment considerations in the primary care setting
Q39170905An update on the safety of psychostimulants for the treatment of attention-deficit/hyperactivity disorder
Q58276674Assessment of Cardiovascular Risks due to Methylphenidate in Six Months of Treatment in Children with Attention Deficit and Hyperactivity Disorder
Q38242438Assessment of potential cardiovascular risks of methylphenidate in comparison with sibutramine: do we need a SCOUT (trial)?
Q34461113Attention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks?
Q37653008Blood pressure and anthropometry in children treated with stimulants: a longitudinal cohort study with an individual approach
Q38240014Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder: an update
Q34063584Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: a nationwide prospective cohort study.
Q83296402Cautious Reassurance: Cardiovascular Risk in the Context of Stimulant Use
Q40654140Evaluation of acute cardiovascular effects of immediate-release methylphenidate in children and adolescents with attention-deficit hyperactivity disorder
Q35624268Exercise outcomes in prevalent users of stimulant medications
Q30859306Exploring parental country of birth differences in the use of psychostimulant medications for ADHD: a whole-population linked data study
Q34257043Genetic targeting of the amphetamine and methylphenidate-sensitive dopamine transporter: on the path to an animal model of attention-deficit hyperactivity disorder
Q38011640Guanfacine Extended Release as Adjunctive Therapy to Psychostimulants in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder
Q38821393Impact of Stimulant Medication Use on Heart Rate and Systolic Blood Pressure During Submaximal Exercise Treadmill Testing in Adolescents
Q38049859Management of Psychotropic Medication Side Effects in Children and Adolescents
Q56095088Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies
Q22061981Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Q34172165Methylphenidate off-label use and safety
Q28282770Practitioner Review: Current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents
Q36373539Prescription stimulants in individuals with and without attention deficit hyperactivity disorder: misuse, cognitive impact, and adverse effects
Q38881600Psychotic Symptoms in Attention-Deficit/Hyperactivity Disorder: An Analysis of the MTA Database
Q38060572Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.
Q30988486Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry
Q38862420The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research
Q41473870Updates on Treatment of Attention-Deficit/Hyperactivity Disorder: Facts, Comments, and Ethical Considerations

Search more.